Ausgabe 1/2022
Inhalt (15 Artikel)
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
- Open Access
- Review Article
Qian Zhang, Wei Wang, Qi Yuan, Li Li, Yu-Chao Wang, Chuan-Zhen Chi, Chun-Hua Xu
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
- Original Article
Takanori Mukozu, Hidenari Nagai, Daigo Matsui, Kunihide Mohri, Go Watanabe, Naoyuki Yoshimine, Makoto Amanuma, Kojiro Kobayashi, Yu Ogino, Yasushi Matsukiyo, Teppei Matsui, Yasuko Daido, Noritaka Wakui, Mie Shinohara, Koichi Momiyama, Koji Higai, Yoshinori Igarashi
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study
- Open Access
- Original Article
Takenori Ichimura, Miwa Hinata, Daisuke Ichikura, Shinya Suzuki
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
- Original Article
Deli Wang, Haiqin Bao
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
- Open Access
- Original Article
Sandra Heuschkel, Theresa Kretschmann, Raphael Teipel, Simone von Bonin, Stephan Richter, Susanne Quick, Nael Alakel, Christoph Röllig, Ekaterina Balaian, Frank Kroschinsky, Holger Knoth, Martin Bornhäuser, Malte von Bonin
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies
- Original Article
Antoinette R. Tan, Nancy Chan, Brian F. Kiesel, Mark N. Stein, Rebecca A. Moss, Jyoti Malhotra, Joseph Aisner, Mansi Shah, Murugesan Gounder, Hongxia Lin, Michael P. Kane, Yong Lin, Jiuping Ji, Alice Chen, Jan H. Beumer, Janice M. Mehnert
4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent
- Original Article
Stephanie Hufnagel, Haiyue Xu, Michael F. Colemam, Solange A. Valdes, Kristyn A. Liu, Stephen D. Hursting, Zhengrong Cui
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
- Open Access
- Original Article
Jennifer E. Hibma, Melissa O’Gorman, Sunil Nepal, Sylvester Pawlak, Katherine Ginman, Yazdi K. Pithavala
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms
- Original Article
Keishi Yoshida, Atsushi Fujita, Hidehiko Narazaki, Takeshi Asano, Yasuhiko Itoh
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
- Open Access
- Original Article
Amita Patnaik, Glen J. Weiss, Drew W. Rasco, Lisa Blaydorn, Amy Mirabella, Murali Beeram, Wei Guo, Sharon Lu, Hadi Danaee, Kristen McEachern, Ellie Im, Jasgit C. Sachdev
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
- Open Access
- Original Article
Sukhmani K. Padda, Karen L. Reckamp, Marianna Koczywas, Joel W. Neal, Jun Kawashima, Shengchun Kong, Daniel B. Huang, Mark Kowalski, Heather A. Wakelee
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
- Original Article
E. M. Tosca, N. Terranova, K. Stuyckens, A. G. Dosne, T. Perera, J. Vialard, P. King, T. Verhulst, J. J. Perez-Ruixo, P. Magni, I. Poggesi
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
- Open Access
- Original Article
Takafumi Ide, Mayu Osawa, Kinjal Sanghavi, Heather E. Vezina
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers
- Clinical Trial Report
Xue Chen, Feng Yang, Jiao Zhao, Qi Tang, Jianfu Heng, Jun Deng, Jin Zhang, Yong Chen, Kunyan Li, Jing Wang
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis
- Retraction Note
Chenggang Li, Zhiming Zhao, Zhipeng Zhou, Rong Liu